1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Επιστημών Υγείας
  4. Τμήμα Ιατρικής
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/18133
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMilionis, H. J.en
dc.contributor.authorGazi, I. F.en
dc.contributor.authorFilippatos, T. D.en
dc.contributor.authorTzovaras, V.en
dc.contributor.authorChasiotis, G.en
dc.contributor.authorGoudevenos, J.en
dc.contributor.authorSeferiadis, K.en
dc.contributor.authorElisaf, M. S.en
dc.date.accessioned2015-11-24T18:50:42Z-
dc.date.available2015-11-24T18:50:42Z-
dc.identifier.issn0003-3197-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/18133-
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectC-Reactive Protein/analysisen
dc.subjectCholesterol, HDL/blooden
dc.subjectCholesterol, LDL/blooden
dc.subjectFemaleen
dc.subjectFluorobenzenes/administration & dosage/adverse effects/*therapeutic useen
dc.subjectHumansen
dc.subjectHydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage/adverseen
dc.subjecteffects/*therapeutic useen
dc.subjectHyperlipidemias/*drug therapyen
dc.subjectKidney/drug effectsen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectPyrimidines/administration & dosage/adverse effects/*therapeutic useen
dc.subjectSulfonamides/administration & dosage/adverse effects/*therapeutic useen
dc.subjectTreatment Outcomeen
dc.titleStarting with rosuvastatin in primary hyperlipidemia--Is there more than lipid lowering?en
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/16193198-
heal.identifier.secondaryhttp://ang.sagepub.com/content/56/5/585.full.pdf-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2005-
heal.abstractThe authors investigated the effects of rosuvastatin, beyond its lipid-lowering activity, on several nonlipid metabolic variables, along with its safety and tolerability, in patients treated for primary hyperlipidemia. Patients (n = 55) with primary hyperlipidemia were open-label assigned to the recommended starting dose of rosuvastatin 10 mg/day, and serum metabolic variables were measured at baseline and after 8 and 20 weeks. Treatment with rosuvastatin produced significant reductions in total cholesterol, low-density lipoprotein cholesterol (LDL-C), apolipoprotein B, nonhigh-density lipoprotein cholesterol (non HDL-C), and triglyceride concentrations, whereas HDL-C, apolipoprotein A-I, and lipoprotein(a) levels did not change significantly from baseline. The LDL-C treatment target was achieved in 71% of patients. No significant variations in renal function parameters (serum creatinine and creatinine clearance), insulin resistance estimates, and serum concentrations of uric acid, total homocysteine, vitamin B12, and folic acid were observed during the period of treatment. High-sensitivity C-reactive protein levels were significantly lowered by rosuvastatin therapy (median values, 3.1 vs 2.0 vs 1.9 mg/L, at 0, 8, and 20 weeks, respectively; p < 0.0001). In conclusion, rosuvastatin at 10 mg/day is a highly effective, safe, and well-tolerated monotherapy option for patients with primary hyperlipidemia, with a favorable antiinflammatory potential and nondeteriorating effects on renal function.en
heal.journalNameAngiologyen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Show simple item record
Files in This Item:
File Description SizeFormat 
Milionis-2005-Starting with rosuva.pdf84.28 kBAdobe PDFView/Open    Request a copy
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons